2014年12月8日讯/生物谷BIOON/--近日，美国血液病学会会议在旧金山召开，会议中有研究者报告，Pharmacyclics和强生的白血病和淋巴瘤药物Imbruvica（布鲁顿氏酪氨酸蛋白激酶）在重度多发性骨髓瘤患者的早期治疗中效果显著，无论是单一用药还是联合用药都能取得良好疗效。
会议上发布的II期临床试验有69名受试者参与，其中包括Imbruvica (ibrutinib)单一疗法以及与地塞米松联合用药的数据。数据表明，Imbruvica (ibrutinib)与地塞米松联合用药效果明显，患者病情发展稳定，平均无进展生存期（PFS）达到了5.6个月，尽管有57%的患者产生了3级或以上不良反应。
基于以上数据，Imbruvica目前正在被考虑参与其他药物联合治疗，比如安进的Kyprolis (carfilzomib)。华盛顿大学医学院的Ravi Vij表示，Imbruvica在其他治疗困难的血癌中也非常有效，临床试验的结果也很有前景。
Imbruvica已被批准用于治疗慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤，目前针对其他类型白血病（如淋巴细胞性淋巴瘤）的治疗仍在研究中。Imbruvica也是当前唯一取得三项FDA突破性治疗认证的药物。
相关英文原文
Pharmacyclics/J&J's Imbruvica shows promise in MM
Pharmacyclics and Johnson & Johnson’s leukaemia and lymphoma drug Imbruvica has shown potential both as a single agent and as combination therapy in heavily pre-treated patients with multiple myeloma.
Phase II data involving 69 patients looked at Imbruvica (ibrutinib) as monotherapy and in combination with dexamethasone have been presented at the American Society of Hematology meeting in San Francisco. Treatment in combination with DEX resulted in positive responses and disease stabilisation which led to a median progression-free survival (PFS) of 5.6 months， though 57% of patients experienced Grade 3 or greater adverse events.
Based on the data， Imbruvica is currently being evaluated as a combo with agents such as Amgen’s Kyprolis (carfilzomib). Ravi Vij of the Washington University School of Medicine， said the drug， an oral Bruton's tyrosine kinase inhibitor， “has shown its effectiveness in other difficult-to-treat blood cancers” and the results of the trial are promising.
Imbruvica is approved for chronic lymphocytic leukaemia and mantle cell lymphoma and is being studied in several blood cancers including small lymphocytic lymphoma. It is the only product to have received three breakthrough therapy designations from the US Food and Drug Administration.